EZH2 GoF
Showing 26 - 50 of 100
Prostate Cancer Trial in Los Angeles (Tazverik)
Not yet recruiting
- Prostate Cancer
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
Sep 30, 2022
Objective Response, Overall Survival Trial in Beijing (VIA combination treatment)
Completed
- Objective Response
- Overall Survival
- VIA combination treatment
-
Beijing, ChinaPeking University People's Hospital
Dec 9, 2022
Follicular Lymphoma, Non Hodgkin Lymphoma, Lymphoma Trial in Edmonds, Issaquah, Seattle (Tazemetostat, Rituximab)
Terminated
- Follicular Lymphoma
- +2 more
-
Edmonds, Washington
- +2 more
Mar 1, 2021
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma Trial in Worldwide (Valemetostat Tosylate)
Recruiting
- Relapsed/Refractory Peripheral T-Cell Lymphoma
- Adult T Cell Leukemia/Lymphoma
- Valemetostat Tosylate
-
Duarte, California
- +59 more
Jun 3, 2022
Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6
Not yet recruiting
- Grade 3b Follicular Lymphoma
- +5 more
- Biospecimen Collection
- +9 more
- (no location specified)
Jun 6, 2023
Diagnostic Platform to Perform Centralized and Standardized
Completed
- Acute Myeloid Leukemia
- NGS techniques
-
Córdoba, Spain
- +6 more
Feb 15, 2021
Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma Trial (Tazemetostat)
Temporarily not available
- Epithelioid Sarcoma (Ex-US Only)
- +19 more
- (no location specified)
Oct 17, 2022
Prostate Cancer Trial in Cleveland (Leuprolide acetate, Apalutamide, Radical prostatectomy)
Completed
- Prostate Cancer
- Leuprolide acetate
- +2 more
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
May 25, 2022
Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)
Not yet recruiting
- Recurrent Ovarian Cancer
-
Pittsburgh, PennsylvaniaMagee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023
Follicular Lymphoma Trial in New York (Mosunetuzumab, Tazemetostat Pill)
Not yet recruiting
- Follicular Lymphoma
- Mosunetuzumab
- Tazemetostat Pill
-
New York, New YorkWeill Cornell Medicine/NewYork-Presbyterian Hospital
Aug 8, 2023
Recurrent DLBCL Germinal Center B-Cell Type, Recurrent Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma Trial (Belinostat,
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- +5 more
- Belinostat
- +2 more
- (no location specified)
Dec 2, 2022
Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma Trial (XNW5004, Pembrolizumab 25 mg/mL Solution for
Not yet recruiting
- Carcinoma
- +7 more
- XNW5004
- Pembrolizumab 25 mg/mL Solution for Injection
- (no location specified)
Aug 31, 2023
Brainstem Cavernous Malformations Trial in Shanghai (Sirolimus)
Not yet recruiting
- Brainstem Cavernous Malformations
-
Shanghai, Shanghai, ChinaHuashan Hospital, Fudan University
Oct 13, 2023
Relapsed Adult AML Trial in Germany (Venetoclax Oral Tablet)
Recruiting
- Relapsed Adult AML
- Refractory AML
- Venetoclax Oral Tablet
-
Augsburg, Germany
- +11 more
Jan 11, 2023
Breast Cancer, Metastatic Cancer Trial in Shanghai (SHR7390, Famitinib, SHR3162)
Recruiting
- Breast Cancer
- Metastatic Cancer
- SHR7390
- +14 more
-
Shanghai, Shanghai, ChinaCancer Hospital Affiliated to Fudan University
Jul 22, 2022
Peripheral Nerve Sheath Tumor Trial in Gainesville (Tazemetostat)
Recruiting
- Peripheral Nerve Sheath Tumor
-
Gainesville, FloridaUniversity of Florida
Jan 4, 2023
Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)
Recruiting
- Relapsed or Refractory Hodgkin Lymphoma
- SHR2554+ SHR1701
- SHR-1701
-
Beijing, Beijing, ChinaHan wei dong
Jun 14, 2023
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (Palbociclib, Tazemetostat,
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Palbociclib
- +4 more
-
Philadelphia, PennsylvaniaThomas Jefferson University Hospital
Jan 13, 2023
Activated PI3K-delta Syndrome, Immunodeficiency Primary Trial in Shanghai (Rapamycin)
Recruiting
- Activated PI3K-delta Syndrome
- Immunodeficiency Primary
-
Shanghai, Shanghai, China
- +1 more
Mar 21, 2022
Chronic Myelomonocytic Leukemia, Leukemia Trial in United States (Ruxolitinib)
Active, not recruiting
- Chronic Myelomonocytic Leukemia
- Leukemia
-
Tampa, Florida
- +4 more
Nov 11, 2022
Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in
Recruiting
- Advanced Malignant Solid Neoplasm
- +44 more
- Biopsy
- +23 more
-
Birmingham, Alabama
- +166 more
Feb 2, 2023
Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)
Not yet recruiting
- Relapsed or Refractory Non-Hodgkin's Lymphoma
-
Beijing, China
- +3 more
Jul 20, 2023